Efficacy and safety of pangenotypic DAAs for chronic HCV infection: real-world data from the RESIST-HCV cohort

Maria Antonietta Di Rosolini ,Salvatore Petta ,F Di Lorenzo,Salvatore Madonia ,A Digiacomo,M Grova ,Gaetano Bertino ,A Montineri,G Squadrito ,A Averna,Maurizio Russello ,A Davì,M.r Cannavò ,V Calvaruso ,M Distefano ,Antonio Craxì ,V Di Marco,G Scifo,G Raimondo ,F Cartabellotta,Agnieszka Micek ,F Salomone ,P Colletti,Carmelo Iacobello ,Antonio Craxì ,A Licata ,F Benanti,L Guarneri ,I Scalisi,Irene Cacciola ,F Latteri

doi:10.1016/j.dld.2022.01.109

Efficacy and safety of pangenotypic DAAs for chronic HCV infection: real-world data from the RESIST-HCV cohort

Maria Antonietta Di Rosolini , Salvatore Petta + Show 29 more

https://doi.org/10.1016/j.dld.2022.01.109

Copy DOI

Journal: Digestive and Liver Disease

Publication Date: Mar 1, 2022

Affiliation: Agenzia Regionale Sanitaria della Puglia, University of Palermo, Ospedale Vincenzo Cervello, University of Catania, University of Messina, Ospedale Garibaldi, Ospedale Buccheri la Ferla Fatebenefratelli, Jagiellonian University, Ospedale Cannizzaro

#Direct Antiviral Agents #Glecaprevir/pibrentasvir + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Background and aims: Real-world data on the efficacy and safety of pangenotypic direct antiviral agents (DAAs) for chronic HCV infection are limited. In this study we assessed the efficacy and safety of sofosbuvir/velpatasvir (SOF/VEL) and glecaprevir/pibrentasvir (GLE/PIB) in the RESIST-HCV cohort.

Full Text